Plain-English translation of NCT07287098 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to treat a specific type of early breast cancer in women who have not yet gone through menopause. Researchers want to see how well this medication works compared to a standard hormone therapy called tamoxifen, and whether adding a medicine to suppress ovarian function makes a difference. The study has two main groups with different treatment lengths and goals.
Women with hormone-sensitive breast cancer need better treatment options that work well and have manageable side effects. This medication is being studied because it may be more effective than current standard treatments for premenopausal women, potentially offering them improved outcomes and quality of life.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will either take the new medication by mouth for up to 29 days (shorter study) or for up to 6 months (longer study). Some participants may also receive an injection to suppress ovarian function. You will have regular clinic visits for blood tests, imaging scans, and to check how you are doing. You may be asked to provide tissue samples from your tumor before and during treatment so researchers can see how the medication is affecting your cancer cells.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States